Publikationen in Zusammenarbeit mit Forschern von Hospital Vall d'Hebron (23)

2023

  1. Noninvasive detection of microsatellite instability in patients with endometrial cancer

    International Journal of Cancer, Vol. 152, Núm. 10, pp. 2206-2217

2022

  1. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

    Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115

  2. Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

    Frontiers in Cell and Developmental Biology, Vol. 10

2021

  1. Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study

    Cancers, Vol. 13, Núm. 18

  2. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 1, pp. 113-124

  3. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  4. M-TRAP: Safety and performance of metastatic tumor cell trap device in advanced ovarian cancer patients

    Gynecologic Oncology, Vol. 161, Núm. 3, pp. 681-686

  5. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Global gene expression characterization of circulating tumor cells in metastasic castration-resistant prostate cancer patients

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-14

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. The role of clonal communication and heterogeneity in breast cancer

    BMC Cancer, Vol. 19, Núm. 1

2018

  1. Human salivary microRNAs in Cancer

    Journal of Cancer, Vol. 9, Núm. 4, pp. 638-649

2017

  1. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma

    International Journal of Cancer, Vol. 140, Núm. 7, pp. 1551-1563

  2. Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers

    Modern Pathology, Vol. 30, Núm. 1, pp. 134-145

  3. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review

    Annals of Oncology, Vol. 28, Núm. 12, pp. 2943-2949

2016

  1. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

    The Lancet Oncology, Vol. 17, Núm. 10, pp. 1386-1395

2012

  1. A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer

    Journal of Cellular and Molecular Medicine, Vol. 16, Núm. 10, pp. 2342-2349

  2. ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas

    Oncogene, Vol. 31, Núm. 45, pp. 4778-4788

2011

  1. Molecular markers of endometrial carcinoma detected in uterine aspirates

    International Journal of Cancer, Vol. 129, Núm. 10, pp. 2435-2444